ClinicalTrials.gg
RecruitingNCT05097898CHF-COV-PUpdated Jun 5, 2023

Chronic Heart Failure With Preserved Ejection Fraction - COngestion eValuation

An interventional study of Clinical examination centered on congestion and Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography in Chronic Heart Failure and Preserved Ejection Fraction, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-05.

Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Heart Failure by Central Hospital, Nancy, France — 9 open to participants now, 10 under way, 1 of them phase 3. Heart Failure · Central Hospital, Nancy, France.

Planned enrollment
Largest of 13
200 · median 103
Started
2022
with 1 other
No phase
12 of 19
8 open now
Registered
12th of 19
by date

Among the 19 studies in Heart Failure by Central Hospital, Nancy, France, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2022, is one of 12 with no phase, and was the 12th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

9 of the 19 studies in Heart Failure by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Heart Failure by Central Hospital, Nancy, France, or all of them as a file.
02

Study summary

Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation.

The main objective of the CHF-COV Preserved study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF with preserved left ventricular ejection fraction that are associated with the risk of all-cause death, hospitalization for acute HF or IV diuretics injection in a day hospital.

03

Conditions studied

  • Chronic Heart Failure
  • Preserved Ejection Fraction

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with chronic acute heart failure with preserved admitted in hospital for scheduled day hospitalization or consultation
  • Patient with preserved left ventricular ejection fraction (≥50%).
  • Age ≥18 years
  • Patients having received complete information regarding the study design and having signed their form.
  • Patient affiliated to or beneficiary of a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Comorbidity for which the is ≤ 3 months
  • Dialysis patient (peritoneal dialysis or hemodialysis) or patients with \<15 ml/min/m2 at inclusion.
  • History of lobectomy or pneumonectomy lung surgery
  • Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.
  • Pregnant woman, parturient or nursing mother
  • Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
  • Adult person who is unable to give consent
  • Person deprived of liberty by a judicial or administrative decision,
  • Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Patients with chronic HFpEF coming for scheduled day hospitalization or consultation

    * Clinical examination focusing on congestion * Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds * Blood sample retrieved for biological assessment and biobanking * Telephone follow-up

    Procedure: Clinical examination centered on congestion · Procedure: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography · Procedure: Blood and urine sample retrieved for biological assessment and biobanking · Other: Telephone follow-up · Behavioral: Kansas City Cardiomyopathy Questionnaire (KCCQ)

Interventions

  • ProcedureClinical examination centered on congestion

    Clinical examination centered on congestion (including the EVEREST, Ambrosy and ASCEND score) will be performed during day hospitalization or consultation

  • ProcedureCardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography

    Cardiac, vena cava, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional/Cardiac echo is optional for patients included in consultation

  • ProcedureBlood and urine sample retrieved for biological assessment and biobanking

    Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation/ Urine analysis is optional for patients included in consultation

  • OtherTelephone follow-up

    Telephone follow-up will be performed 3, 12 and 24

  • BehavioralKansas City Cardiomyopathy Questionnaire (KCCQ)

    Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge

06

What researchers measure

Primary outcomes

  1. Rate of death from all causes

    composite endpoint : rate of death from all causes, hospitalisation for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following inclusion (with outcome 2 and 3)

    Time frame: 24 months after inclusion

  2. Rate of hospitalisation for acute heart failure

    composite endpoint : rate of death from all causes, hospitalisation for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following inclusion (with outcome 1 and 3)

    Time frame: 24 months after inclusion

  3. Rate of day-hospital or in-home IV diuretics injection for acute HF

    composite endpoint : rate of death from all causes, hospitalisation for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following inclusion (with outcome 1 and 2)

    Time frame: 24 months after inclusion

Secondary outcomes

  1. Number of B-lines measured in lung echography

    Time frame: At baseline

  2. Rate of death from all causes

    composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after inclusion (with outcome 6)

    Time frame: 24 months after inclusion

  3. Rate of hospitalisation for acute heart failure

    composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after inclusion (with outcome 5)

    Time frame: 24 months after inclusion

  4. Rate of death from all causes

    Time frame: 24 months after inclusion

  5. Rate of hospitalisation for acute heart failure

    composite endpoint: Rate of hospitalisation for acute heart failure or day-hospital/in-home IV diuretics injection for acute HF 24 months after inclusion (with outcome 9)

    Time frame: 24 months after day hospitalization

  6. Rate of day-hospital or in-home IV diuretics injection for acute HF

    composite endpoint: Rate of hospitalisation for acute heart failure or day-hospital/in-home IV diuretics injection for acute HF 24 months after inclusion (with outcome 8)

    Time frame: 24 months after inclusion

  7. Rate of hospitalisation for cardiovascular reason

    Time frame: 24 months after inclusion

  8. Rate of death from all causes

    composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after inclusion (with outcome 12)

    Time frame: 24 months after inclusion

  9. Rate of hospitalisation for acute heart failure

    composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after inclusion (with outcome 11)

    Time frame: 24 months after inclusion

  10. Rate of cardiovascular death

    Time frame: 24 months after inclusion

  11. NYHA (New York Heart Association) class measured

    Time frame: 3, 12 and 24 months after inclusion

  12. Natriuretic peptides

    BNP or Nt-Pro BNP

    Time frame: At baseline

  13. Renal function

    Assessed by glomerular filtration rate

    Time frame: At baseline

  14. Plasma volume

    Calculated from haemoglobin and haematocrit value

    Time frame: At baseline

  15. Rate of bilirubin

    Time frame: At baseline

  16. Rate of ASAT

    Time frame: At baseline

  17. Rate of ALAT

    Time frame: At baseline

  18. Rate of V factor

    Time frame: At baseline

  19. Blood potassium concentration

    Time frame: At baseline

  20. Liver elastography value

    Measured with Fibroscan®

    Time frame: At inclusion

  21. Quality of life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Time frame: At inclusion and 3, 6 and 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2028, 76 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 76 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2021
First posted
Oct 28, 2021
StartActual
Aug 10, 2022
Primary completionEst.
Dec 10, 2028
CompletionEst.
Jun 10, 2029
Last update
Jun 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05097898
Responsible party
Pr. Nicolas GIRERD (Principal Investigator, Central Hospital, Nancy, France) — Principal investigator
First posted
Oct 28, 2021
Start date
Aug 10, 2022
Primary completion
Dec 10, 2028 (estimated)
Completion
Jun 10, 2029 (estimated)
Last update
Jun 5, 2023

Study contacts

Nicolas GIRERD, MD, PhD
Contact
n.girerd@chru-nancy.fr
+ 33 3 83 15 73 22 ext. + 33 3
Sanae BOUALI
Contact
s.bouali@chru-nancy.fr
+ 33 3 83 15 73 22 ext. + 33 3

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion